A specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction

Strong financials paving the way for broadening the business - Interim Report Q3 2019

OCTOBER 24, 2019 – With continued strong financials in the quarter, we are on track to deliver a very strong year. The development was mainly driven by Zubsolv® in the US and lower COGS, but also by some adjustment of lower returns and rebates which compensated for the lower volume as a result of some formulary changes in the exclusive plans.

Presentation of the Q3 2019 Interim Report

OCTOBER 17, 2019 - Listen to Nikolaj Sørensen CEO and Joseph DeFeo CFO presenting the report and answering questions about the latest development and the way going forward.

Good progress in pipeline

Orexo has a strong history of developing new products approved in markets all over the world. In order to ensure a continued inflow of new improved drugs, the work at the development department in Uppsala, Sweden, has intensified. Filling an unmet need among healthcare professionals and patients is the key in the work of developing new innovative products for treatment of opioid addiction in all phases.

Our CEO about entering Digital Therapies

AUGUST 21, 2019 - Orexo will together with its partner GAIA AG develop and commercialize a new digital therapy to increase access and improve treatments of Opioid Use Disorder. Why digital therapies, why now and why together with GAIA? Nikolaj Sørensen, CEO, answers this questions in the latest version of Orexo Our View.